Skip to Content
Market Update

A Dramatic Reversal in the Market

Those value funds you own that have annoyed you? Take a look now. Many are surging.

Mentioned: , , , , , , , , ,

Morningstar FundInvestor editor Russ Kinnel sent this alert to his readers this morning. 

Wow, what a time in the markets. Last week, the markets rallied as it became apparent that Joe Biden would win the election for U.S. president and that Republicans would gain some seats in the House. But this week has been even more interesting. Over the weekend, the election was called for Biden, and on Monday morning, Pfizer (PFE) announced a coronavirus vaccine with 90% efficacy that would start to be rolled out by December. Also, experts explained that good news made it more likely that other vaccines would prove effective.

The result was the great reversal in fortune that market watchers have expected for years. Small value had a massive rally and growth declined. As you know, growth has been running laps around value thanks to super-fast growers like Amazon.com (AMZN) and Tesla (TSLA). But since COVID-19 hit last March, the dynamic gap grew greater. Value tends to be more economically sensitive, and the recession came out of nowhere. Thus, energy, manufacturing, restaurants, and retailers other than supermarkets and Amazon got crushed. On the flip side, Zoom (ZM), Peloton (PTON), Amazon, and others profited from everyone staying home.

Those value funds you own that have annoyed you? Take a look now. Many are surging.

The top performer for the month so far is Oakmark International (OAKIX), which was up 21.3% in just the first 10 days of November. Causeway International Value (CIVVX) was up 21.2%, Causeway Global Value (CGVVX) was up 19.9%, and Oakmark Global (OAKGX) was up 17.1% through Tuesday, Nov. 10. Other big value winners include the downtrodden Hotchkis & Wiley Mid-Cap Value (HWMAX), up 16.7%; Fidelity Small Cap Value (FCPVX), up 16.1%; and Dodge & Cox International Stock (DODFX), up 15.7%. On a relative basis, Fidelity Capital & Income (FAGIX) has also been impressive, with a 4.5% gain that put it in the top percentile for the month.

In absolute terms, the funds hurting most are mostly those with some interest-rate risk rather than growth stocks because the growth stocks were invited to last week's party even though they were shut out of this week's vaccine rally. Vanguard Long-Term Treasury (VUSTX) shed 1.5% in November's first 10 days. Vanguard Total International Bond Index (VTABX) fell 0.4%. Mortgages lost a bit as evidenced by Fidelity Mortgage Securities' (FMSFX) 0.2% decline and DoubleLine Total Return Bond's (DBLTX) 0.1% drop.

A couple of noteworthy relative underperformers are Morgan Stanley Institutional Growth (MSEGX), which was bottom 3% with a 2.6% gain as its Internet-heavy portfolio took a breather. The fund is still up an insane 82.1% for all of 2020, so I'm sure no one's complaining. Ariel International's (AINTX) quality portfolio is also lagging as quality stocks often do in a cyclical-driven rally. The fund's 6.2% month-to-date gain puts it in the bottom 2% of its peer group.

The 2020 Picture
Although small value has made up a lot of ground, growth still dominates the 2020 picture. Large growth is up 24.8%, followed by mid- and small-growth at 23.0% and 20.0%, respectively. Small value is down 6.7% for the year, followed by mid-value's negative 4.9% return and large value's negative 3.2% return.

Russel Kinnel has a position in the following securities mentioned above: DODFX. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.